[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607957":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":28,"centralContacts":33,"locations":43,"responsibleParty":99,"collaborators":101,"id":105,"slug":106,"hasResults":107,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":107,"sex":113,"minAge":114,"maxAge":115,"enrollmentInfo":116,"targetDuration":28,"studyType":119,"phases":120,"briefSummary":122,"conditions":123,"keywords":125,"overallStatus":87,"whyStopped":28,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":132,"completionDateStruct":133,"leadSponsor":135,"locationsCount":136},{"fullName":5,"class":6},"University Hospital, Bordeaux","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Radiofrequency endometrial ablation","EXPERIMENTAL","Radiofrequency endometrial ablation performed using NovaSure®",[13],"Procedure: Radiofrequency endometrial ablation",{"label":15,"type":10,"description":16,"interventionNames":17},"Uterine artery embolization","Uterine artery embolization carried out under the guidance of digital subtraction angiography",[18],"Procedure: Uterine artery embolization",{"label":20,"type":21,"description":20,"interventionNames":22},"Hysterectomy","ACTIVE_COMPARATOR",[23],"Procedure: Hysterectomy",[25,29,31],{"type":26,"name":9,"description":9,"armGroupLabels":27,"otherNames":28},"PROCEDURE",[9],null,{"type":26,"name":15,"description":15,"armGroupLabels":30,"otherNames":28},[15],{"type":26,"name":20,"description":20,"armGroupLabels":32,"otherNames":28},[20],[34,39],{"name":35,"role":36,"phone":37,"phoneExt":28,"email":38},"Jean-Luc Brun, MD, PhD","CONTACT","+33 5 56 79 59 85","jean-luc.brun@chu-bordeaux.fr",{"name":40,"role":36,"phone":41,"phoneExt":28,"email":42},"Marc Sapoval, MD, PhD","+33 1 56 09 37 41","marc.sapoval2@aphp.fr",[44,59,72,85],{"facility":45,"status":46,"city":47,"state":28,"zip":28,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"CHU Bordeaux","NOT_YET_RECRUITING","Bordeaux","France","FR",{"type":51,"coordinates":52},"Point",[53,54],-0.58046,44.84124,{"lat":54,"lon":53},[57],{"name":58,"role":36,"phone":37,"phoneExt":28,"email":38},"Jean-Luc BRUN, MD, PhD",{"facility":60,"status":46,"city":61,"state":28,"zip":62,"country":48,"countryCode":49,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"APHP - Hôpital Antoine Béclère","Clamart","92140",{"type":51,"coordinates":64},[65,66],2.26692,48.80299,{"lat":66,"lon":65},[69],{"name":70,"role":36,"phone":28,"phoneExt":28,"email":71},"Xavier DEFFIEUX","xavier.deffieux@aphp.fr",{"facility":73,"status":46,"city":74,"state":28,"zip":75,"country":48,"countryCode":49,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"CHU Limoges","Limoges","87042",{"type":51,"coordinates":77},[78,79],1.24759,45.83362,{"lat":79,"lon":78},[82],{"name":83,"role":36,"phone":28,"phoneExt":28,"email":84},"Tristan GAUTHIER","tristan.gauthier@chu-limoges.fr",{"facility":86,"status":87,"city":88,"state":28,"zip":89,"country":48,"countryCode":49,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"CHU Montpellier","RECRUITING","Montpellier","34090",{"type":51,"coordinates":91},[92,93],3.87635,43.61093,{"lat":93,"lon":92},[96],{"name":97,"role":36,"phone":28,"phoneExt":28,"email":98},"Martha DURAES","m-duraes@chu-montpellier.fr",{"type":100,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR",[102],{"name":103,"class":104},"French Ministry of Social Affairs and Health","UNKNOWN","100607957","radiofrequency-endometrial-ablation-or-uterine-artery-embolization-for-treatment-of-adenomyosis-related-abnormal-uterine-bleeding-100607957",false,"NCT07195305","Radiofrequency Endometrial Ablation or Uterine Artery Embolization for Treatment of Adenomyosis-related Abnormal Uterine Bleeding","Radiofrequency Endometrial Ablation or Uterine Artery Embolization for Women With Adenomyosis-related Abnormal Uterine Bleeding Eligible for Hysterectomy: a Non-inferiority Randomized Clinical Trial Comparing Each Intervention to Hysterectomy","ADENOTREAT","Inclusion Criteria:\n\n* Premenopausal women aged 30 to 50 years\n* Women who had at least 3 prior months failed medical therapy, or a contraindication to medical therapy, or refused medical therapy for adenomyosis-related AUB\n* Symptomatic pure internal adenomyosis or dominant adenomyosis (with less than 5 concurrent uterine fibroids type 3-7 \\\u003C 5 cm) confirmed by MRI (\\\u003C 6 months) according to ESHRE criteria\n* AUB defined as a PBAC score \\>100 at baseline\n* Uterine ultrasound measurement of 6.0-12.0 cm (external os to internal fundus)\n* Women with an indication for hysterectomy for adenomyosis-related AUB and accepting hysterectomy\n* Highly effective contraception for women of childbearing potential, maintained until the onset of menopause\n* Affiliated or beneficiary of health insurance\n* Signed informed consent\n\nExclusion Criteria:\n\n* Uterine cavity abnormality or obstruction confirmed via imaging modalities or hysteroscopy\n* Deep infiltrating posterior subperitoneal endometriosis involving contiguous digestive tract structures\n* Uterine malignancy within the last five years\n* Secreting ovarian tumor\n* Atypical endometrial hyperplasia\n* Unaddressed high grade cervical intra-epithelial lesions\n* Active sexually transmitted disease or pelvic inflammatory disease\n* Documented or suspected coagulopathies or long-term blood-thinner medications\n* Prior transmural myomectomy or prior endometrial ablation\n* Plasma FSH level \\> 40 IU\u002FmL\n* Any contraindication to angiography (including iodine allergy and creatinine clearance \\\u003C 60mL\u002Fmin)\n* Any contraindication to MRI (claustrophobia, pace maker, etc.)\n* Any contraindication to the use of Embosphere®, Embozene® or NovaSure® according to the instruction for use\n* Women who are pregnant, breastfeeding, or who are planning to become pregnant\n* Any condition or any situation that would prohibit women from coming to the investigational center for the 6 months follow-up\n* Women unable to understand the nature, risks, significance and implications of the clinical investigation\n* Women under legal protection","FEMALE","30 Years","50 Years",{"count":117,"type":118},230,"ESTIMATED","INTERVENTIONAL",[121],"NA","The present study aims to compare the efficacy (menstrual blood loss, pain, quality of life) and the safety (complications, recovery) of each conservative intervention (RFA, UAE) versus hysterectomy for the treatment of adenomyosis-related abnormal uterine bleeding, up to 2 years",[124],"Abnormal Uterine Bleeding Due to Adenomyosis (Disorder)",[9,15,20,126,127],"Adenomyosis","Abnormal uterine bleeding","2026-04-17",{"date":130,"type":131},"2026-04-20","ACTUAL",{"date":128,"type":131},{"date":134,"type":118},"2029-05",{"name":5,"class":6},4]